Royalty Pharma PLCNASDAQ:RPRX
- LAST PRICE28.3550
- TODAY'S CHANGE (%)0.2850 (1.0153%)
- Bid / Lots28.3500/ 6
- Ask / Lots28.3600/ 4
- Open / Previous Close28.2200 / 28.0700
- Day Range
- 52 Week Range
- Volume566,704
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPRX |
|---|---|---|
| 09:32 ET | 18616 | 28.25 |
| 09:34 ET | 2288 | 28.23 |
| 09:36 ET | 2750 | 28.23 |
| 09:38 ET | 3467 | 28.23 |
| 09:39 ET | 104086 | 28.23 |
| 09:41 ET | 8265 | 28.24 |
| 09:43 ET | 4246 | 28.27 |
| 09:45 ET | 20969 | 28.29 |
| 09:48 ET | 3971 | 28.25 |
| 09:50 ET | 9829 | 28.24 |
| 09:52 ET | 2151 | 28.28 |
| 09:54 ET | 2800 | 28.25 |
| 09:56 ET | 9011 | 28.15 |
| 09:57 ET | 23205 | 28.19 |
| 09:59 ET | 200 | 28.19 |
| 10:01 ET | 5474 | 28.16 |
| 10:03 ET | 2970 | 28.135 |
| 10:06 ET | 1435 | 28.15 |
| 10:08 ET | 10932 | 28.135 |
| 10:10 ET | 3761 | 28.15 |
| 10:12 ET | 1047 | 28.17 |
| 10:14 ET | 2864 | 28.185 |
| 10:15 ET | 3161 | 28.135 |
| 10:17 ET | 1874 | 28.12 |
| 10:19 ET | 700 | 28.12 |
| 10:21 ET | 500 | 28.115 |
| 10:24 ET | 1379 | 28.135 |
| 10:26 ET | 2547 | 28.125 |
| 10:28 ET | 6287 | 28.145 |
| 10:30 ET | 500 | 28.155 |
| 10:32 ET | 200 | 28.179 |
| 10:33 ET | 2497 | 28.1725 |
| 10:35 ET | 7717 | 28.225 |
| 10:37 ET | 2549 | 28.285 |
| 10:39 ET | 4045 | 28.29 |
| 10:42 ET | 3516 | 28.26 |
| 10:44 ET | 2042 | 28.265 |
| 10:46 ET | 674 | 28.27 |
| 10:48 ET | 1472 | 28.27 |
| 10:50 ET | 2828 | 28.275 |
| 10:51 ET | 2985 | 28.26 |
| 10:53 ET | 1696 | 28.24 |
| 10:55 ET | 2777 | 28.265 |
| 10:57 ET | 7367 | 28.275 |
| 11:00 ET | 1200 | 28.285 |
| 11:02 ET | 2033 | 28.32 |
| 11:04 ET | 12052 | 28.3 |
| 11:06 ET | 112816 | 28.27 |
| 11:08 ET | 10325 | 28.265 |
| 11:09 ET | 3653 | 28.27 |
| 11:11 ET | 3800 | 28.3 |
| 11:13 ET | 3288 | 28.3 |
| 11:15 ET | 3853 | 28.31 |
| 11:18 ET | 4537 | 28.34 |
| 11:20 ET | 3374 | 28.36 |
| 11:22 ET | 2466 | 28.32 |
| 11:24 ET | 1542 | 28.325 |
| 11:26 ET | 4409 | 28.34 |
| 11:27 ET | 1818 | 28.34 |
| 11:29 ET | 3017 | 28.34 |
| 11:31 ET | 1300 | 28.355 |
May 13, 2024
Royalty Pharma to Present at Upcoming Investor Conferences, from 8:15AM ET on Monday May 13, 2024 by Dow Jones
8:15AM ET on Monday May 13, 2024 by Dow Jones
May 9, 2024
Royalty Pharma Reports First Quarter 2024 Results, from 7:00AM ET on Thursday May 09, 2024 by Dow Jones
7:00AM ET on Thursday May 09, 2024 by Dow Jones*DJ Royalty Pharma 1Q Net $5M >RPRX, from 7:00AM ET on Thursday May 09, 2024 by Dow Jones
7:00AM ET on Thursday May 09, 2024 by Dow JonesRoyalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab, from 6:45AM ET on Thursday May 09, 2024 by Dow Jones
6:45AM ET on Thursday May 09, 2024 by Dow JonesPress Release: Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab, from 6:45AM ET on Thursday May 09, 2024 by Dow Jones
6:45AM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Royalty Pharma PLC | 16.8B | 15.9x | +1.83% |
Amneal Pharmaceuticals Inc | 2.1B | -12.3x | --- |
Catalent Inc | 10.0B | -8.6x | --- |
Jazz Pharmaceuticals PLC | 7.1B | 22.7x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Prestige Consumer Healthcare Inc | 3.5B | -40.7x | --- |
Company Information
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Contact Information
- Headquarters
- 110 East 59th StreetNEW YORK, NY, United States 10022
- Phone
- 212-883-0200
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Pablo Legorreta
- Vice Chairman, Executive Vice President
- Christopher Hite
- Chief Financial Officer, Executive Vice President
- Terrance Coyne
- Executive Vice President - Investments and Chief Legal Officer
- George Lloyd
- Executive Vice President - Research and Investments
- Marshall Urist
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.8B |
|---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 597.4M |
Dividend Yield | 2.96% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 05-16-24 |
Pay Date | 06-14-24 |
Beta | 0.47 |
EPS | $1.78 |
Book Value | $14.61 |
P/E Ratio | 15.9x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | 14.1x |
Operating Margin | 41.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
